insitro

insitro describes itself as applying causal AI to human health, combining more than 20 petabytes of automated cellular experiments with population-scale genetics to build Physical AI systems aimed at revealing the causal drivers of human disease and delivering targeted therapeutics. Its Virtual Human platform is described as a genetically anchored, causal AI engine built on an integrated multimodal corpus of human clinical and cellular data, intended to identify causal disease targets before candidate optimization. Its TherML engine is described as a modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics. Daphne Koller is identified as Founder & CEO. Wikidata describes insitro, inc. as a company in South San Francisco, United States.

insitro presents itself as a company making medicines differently, combining 20+ petabytes of automated cellular experiments with population-scale genetics to build Physical AI systems that reveal the true causal drivers of human disease and deliver targeted therapeutics. It states that it has built a culture where life scientists, data scientists, engineers, and drug hunters work together to identify important questions, design and scale experiments, build models, and analyze results. Wikidata describes insitro, inc. as a company in South San Francisco, United States.

Causal AI for human health and AI-driven drug discovery and therapeutics design.

• Virtual Human

  A genetically anchored, causal AI engine built on an integrated multimodal corpus of human clinical and cellular data, intended to reveal how disease begins, progresses, and can be resolved, and to identify causal disease targets prior to candidate optimization.

• TherML

  A modality-agnostic, AI-driven therapeutics design engine spanning small molecules, oligonucleotides, and complex biologics, matching the best-fit modality to each target and indication.

• Unconfirmed

  Reported2026.10.15

  AstraZeneca strikes $40 million AI drug discovery deal with insitro[3]阿斯利康与insitro达成4000万美元AI药物研发合作协议news.google.com

  AstraZeneca has struck a $40 million artificial intelligence drug discovery deal with insitro, as reported by Reuters.

• 2020.10.29

  Reported2020.10.29

  Bristol Myers Squibb and insitro agree to develop drugs for ALS and FTD[4]Bristol Myers Squibb与insitro达成ALS和额颞叶痴呆药物研发合作pharmatimes.com

  Bristol Myers Squibb signed a five-year collaboration agreement with insitro to develop drugs for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The agreement provides for an upfront payment and potential milestone payments and sales royalties.

• Unconfirmed

  AstraZeneca announces drug discovery collaboration with insitro[5]阿斯利康宣布与insitro开展药物发现合作ajbell.co.uk

  AstraZeneca announced that it had entered into a strategic drug discovery collaboration and licensing agreement with insitro.

Read more

1. 1Making Medicines Differently - insitroinsitro.com
2. 2insitro, inc.wikidata.org
3. 3阿斯利康与insitro达成4000万美元AI药物研发合作协议news.google.com
4. 4Bristol Myers Squibb与insitro达成ALS和额颞叶痴呆药物研发合作pharmatimes.com
5. 5阿斯利康宣布与insitro开展药物发现合作ajbell.co.uk